Correction: Antitumoral gene-based strategy involving nitric oxide synthase type III overexpression in hepatocellular carcinoma (Gene Therapy, (2016), 23, 1, (67-77), 10.1038/gt.2015.79);Antitumoral gene-based strategy involving nitric oxide synthase type III overexpression in hepatocellular carcinoma

Gene Therapy

Volumn 23, Issue 1, 2016, Pages 67-77

  De La Rosa, A J ^a   Rodriguez Hernandez A ^a   Gonzalez R ^b   Romero Brufau, S ^c   Navarro Villaran E ^a   Barrera Pulido, L ^a   Pereira, S ^a   Marin L M ^a   Lopez Bernal F ^a   Alamo J M ^a,d   Gomez Bravo M A ^a,d   Padillo, F J ^a,d   Muntane J ^a,d,e  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c MAYO CLINIC   (United States)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; COMPLEMENTARY DNA; CYCLINE; FAS ANTIGEN; FAS LIGAND; GREEN FLUORESCENT PROTEIN; HISTONE H3; LUCIFERASE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE 3; PROTEIN P53; UNCLASSIFIED DRUG; CASP3 PROTEIN, MOUSE; CASP8 PROTEIN, MOUSE; CASP9 PROTEIN, MOUSE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NOS3 PROTEIN, MOUSE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MOUSE; NITROSATIVE STRESS; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ROUS SARCOMA VIRUS; TUMOR CELL INOCULATION; UPREGULATION; VIRAL GENE THERAPY; ADENOVIRIDAE; ANIMAL; CARCINOMA, HEPATOCELLULAR; CYTOLOGY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ADENOVIRIDAE; ALPHA-FETOPROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA, COMPLEMENTARY; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GENETIC VECTORS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE III; RNA, SMALL INTERFERING; ROUS SARCOMA VIRUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84955210300     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/s41434-023-00397-y     Document Type: Erratum

References (43)

1. Lancaster Jr JR. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide 1997; 1: 18-30
2. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615
3. Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013; 34: 503-512
4. Muntane J, la Mata MD. Nitric oxide and cancer. World J Hepatol 2010; 2: 337-344
5. McCarthy HO, Coulter JA, Robson T, Hirst DG. Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. J Pharm Pharmacol 2008; 60: 999-1017
6. Muntane J, De la Rosa AJ, Marin LM, Padillo FJ. Nitric oxide and cell death in liver cancer cells. Mitochondrion 2013; 13: 257-262
7. Aguilar-Melero P, Ferrin G, Muntane J. Effects of nitric oxide synthase-3 overexpression on post-translational modifications and cell survival in HepG2 cells. J Proteomics 2012; 75: 740-755
8. Bian K, Murad F. What is next in nitric oxide research?. From cardiovascular system to cancer biology. Nitric Oxide 2014; 43: 3-7
9. Hirst D, Robson T. Targeting nitric oxide for cancer therapy. J Pharm Pharmacol 2007; 59: 3-13
10. Li CQ, Wogan GN. Nitric oxide as a modulator of apoptosis. Cancer Lett 2005; 226: 1-15
11. Vieira H, Kroemer G. Mitochondria as targets of apoptosis regulation by nitric oxide. IUBMB Life 2003; 55: 613-616
12. Siendones E, Fouad D, Abou-Elella AM, Quintero A, Barrera P, Muntane J. Role of nitric oxide in D-galactosamine-induced cell death and its protection by PGE1 in cultured hepatocytes. Nitric Oxide 2003; 8: 133-143
13. Yasuda H, Nakayama K, Watanabe M, Suzuki S, Fuji H, Okinaga S et al. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 2006; 12: 6748-6757
14. Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009; 74: 878-883
15. Takabuchi S, Hirota K, Nishi K, Oda S, Oda T, Shingu K et al. The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxidesoluble guanylyl cyclase pathway. Biochem Biophys Res Commun 2004; 324: 417-423
16. Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D, Yeung K. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide 2008; 19: 152-157
17. Siendones E, Fouad D, Diaz-Guerra MJ, de la Mata M, Bosca L, Muntane J, PGE1-induced NO. reduces apoptosis by D-galactosamine through attenuation of NFkappaB and NOS-2 expression in rat hepatocytes. Hepatology 2004; 40: 1295-1303
18. Tong L, Wu S. The role of constitutive nitric-oxide synthase in ultraviolet B lightinduced nuclear factor kappaB activity. J Biol Chem 2014; 289: 26658-26668
19. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1-12
20. Akazawa Y, Gores GJ. Death receptor-mediated liver injury. Semin Liver Dis 2007; 27: 327-338
21. Seitz SJ, Schleithoff ES, Koch A, Schuster A, Teufel A, Staib F et al. Chemotherapyinduced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer 2010; 126: 2049-2066
22. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002; 54: 431-467
23. Leon-Bollotte L, Subramaniam S, Cauvard O, Plenchette-Colas S, Paul C, Godard C et al. S-nitrosylation of the death receptor fas promotes fas ligand-mediated apoptosis in cancer cells. Gastroenterology 2011; 140: 2009-2018; 2018 e1-4
24. Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 2006; 44: 1441-1451
25. Palanisamy AP, Cheng G, Sutter AG, Liu J, Lewin DN, Chao J et al. Adenovirusmediated eNOS expression augments liver injury after ischemia/reperfusion in mice. PLoS One 2014; 9: e93304
26. Matei V, Rodriguez-Vilarrupla A, Deulofeu R, Colomer D, Fernandez M, Bosch J et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006; 44: 44-52
27. Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed Fel Z, Davies N, Sharma V et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol 2015; 62: 325-331
28. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 2011; 9: 171
29. Higaki K, Yano H, Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 1996; 149: 429-437
30. Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS et al. Expression of Fas and Fasrelated molecules in human hepatocellular carcinoma. Hum Pathol 2001; 32: 250-256
31. Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H et al. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 2007; 46: 77-88
32. Hayden MA, Lange PA, Nakayama DK. Nitric oxide and cyclic guanosine monophosphate stimulate apoptosis via activation of the Fas-FasL pathway. J Surg Res 2001; 101: 183-189
33. Martin LJ, Chen K, Liu Z. Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. J Neurosci 2005; 25: 6449-6459
34. Gonzalez R, Ferrin G, Aguilar-Melero P, Ranchal I, Linares CI, Bello RI et al. Targeting hepatoma using nitric oxide donor strategies. Antioxid Redox Signal 2013; 18: 491-506
35. Xu W, Liu L, Charles IG. Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J 2002; 16: 213-215
36. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998; 4: 1371-1376
37. Zhang J, Dawson VL, Dawson TM, Snyder SH. Nitric oxide activation of poly (ADPribose) synthetase in neurotoxicity. Science 1994; 263: 687-689
38. Pande K, Ueda R, Machemer T, Sathe M, Tsai V, Brin E et al. Cancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviraltriggered anaphylactoid-type reactions. Mol Ther 2009; 17: 508-515
39. Gonin S, Diaz-Latoud C, Richard MJ, Ursini MV, Imbo A, Manero F et al. p53/Tantigen complex disruption in T-antigen transformed NIH3T3 fibroblasts exposed to oxidative stress: correlation with the appearance of a Fas/APO-1/CD95 dependent, caspase independent, necrotic pathway. Oncogene 1999; 18: 8011-8023
40. Minana JB, Gomez-Cambronero L, Lloret A, Pallardo FV, Del Olmo J, Escudero A et al. Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology 2002; 35: 1205-1214
41. Reinehr R, Haussinger D. CD95 activation in the liver: ion fluxes and oxidative signaling. Arch Biochem Biophys 2007; 462: 124-131
42. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15 N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-138
43. Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE 2001; 2001: pl1